Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2

Conditions

Prostatic Neoplasms 1Pain 1Neoplasm Metastasis 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × tandutinib × Genitourinary × Clear all
NCT00408902 2017-11-22

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

NCT00390468 2014-05-28

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 5 charts
Genitourinary

Neoplasm Metastasis, Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡